To evaluate the anti-tumor capacity of in vitro–expanded TILs with contrasting CD4+ vs. CD8+ TIL ratios, RepTILs were transferred to tumor-implant-bearing PDX mice with constitutive human IL-2 expression to maintain adequate TIL levels in vivo. The gene discussed is CD4; the disease is neoplasm.